Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• KRAS mutations are key drivers in various solid tumors, posing significant therapeutic challenges due to the oncogene's structure.
• Covalent KRAS inhibitors offer a novel approach by targeting KRAS G12C mutants, leading to clinical responses in patients with KRAS G12C-mutant solid tumors, including colorectal cancer (CRC).

Purpose of the Study:

• To review recent clinical advancements in targeting KRAS G12C for KRAS G12C-mutant CRC management.
• To provide an update on alternative RAS-targeting strategies and discuss future therapeutic directions for RAS-mutant CRC.

Main Methods:

• Literature review of clinical trials and research on KRAS inhibitors and RAS-targeting therapies.
• Analysis of the biological characteristics of RAS-mutant CRC and associated resistance mechanisms.

Main Results:

• KRAS G12C inhibitors have demonstrated significant clinical efficacy in patients with KRAS G12C-mutant solid tumors, including CRC.
• Ongoing clinical trials are investigating other allele-specific, panKRAS, and panRAS inhibitors.

Conclusions:

• KRAS G12C inhibitors represent a significant therapeutic advance for KRAS G12C-mutant CRC.
• Combining KRAS inhibitors with anti-EGFR therapy and exploring novel strategies are crucial for overcoming resistance and improving outcomes in RAS-mutant CRC.